Structure de mise en forme 2 colonnes


Brief Description

Kirkstall is developing instruments and protocols for toxicity and safety testing aimed at the pharmaceutical, chemical and cosmetics industries, using in-vitro technology that will reduce the use of animal testing. The company (SME status) has been operating for just over one year and is forming partnerships with several leading Universities and Research Institutes to commercialise the results of their research. Two people are employed and 2007 turnover was 150,000 €.      

Department involved

The whole company will be involved in InLiveTox.     

Activities in the project

Kirkstall’s role in the project is to promote the dissemination of project results and ensure these are commercialised in the most efficient way, not only for the benefit of the project beneficiaries, but also for European industry in general as well for the health and well being of European citizens and those throughout the world by partners in the ICPC. Kirkstall will manage the Users and Authorities groups. Kirkstall will provide ‘market pull’ by ensuring the specifications for the technology platform being developed meet the needs of the research community. It will provide a framework for managing Intellectual Property, capturing inventions and innovations made during the project and ensuring they are protected. It will assist in developing a Commercialisation Strategy that is consistent with the commercial aspirations of the beneficiaries and the Users (with the support of the Users Group). The project results will be  disseminated through workshops, conference papers, training courses and web  page. Authorities will be targeted via the Authorities Group. Kirkstall will act as an RTD beneficiary and like all beneficiaries will benefit from any subsequent commercial product development following the project. No IP rights will belong solely to Kirkstall.    

Expertise in these activities / Previous experiences

Kirkstall’s staff have been assisting and advising for commercialisation of research results in Universities since 1992 and have been involved in the creation of 4 start-up companies. Between 1997 and 2001, the Managing Director of KIRKSTALL was a Coordinator in the EU Europractice project on micro  technology, working with leading research institutes and training organisations.  KIRKSTALL’s experience covers scale up of novel microelectronic manufacturing processes, design of complex systems, management of collaborative development teams both within large corporations in USA and Europe. More information is available in their website: n      

Key people involved

Dr John Malcolm Wilkinson is in the Company since its foundation in 2006. He is responsible for business development and managing the product portfolio. He has over 25 years experience in high technology industry covering R&D management, Product Development, Marketing &Sales, Corporate Technology Strategy and Technology Transfer inter and intra company. He has been an Evaluator,Beneficiary, Coordinator and Reviewer of EU projects. n      

Some relevant publications / Patent

KIRKSTALL  is not contributing technology, but in the processes of successful commercialisation of RTD results, KIRKSTALL  have published extensively. See for example: Commercialisation of Microsystems Conference, Tampa, Florida, September 2006